contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


prostatype-genomics-aktiespararna-sees-large-upside-for-the-share-in-research-report-with-target-price-012-sek-per-share

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Prostatype Genomics operates in the medical technology sector. The company specializes in the development of medical genetic tests used for the identification, analysis and further follow-up of prostate cancer. In addition to its main business, related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic market. The head office is located in Nacka Strand.

Prostatype Genomics

Prostatype Genomics (”Prostatype Genomics” or ”the Company”) announces that Aktiespararna has published a research report in which the target price for the Company is set at 0.12 SEK per share...

<div class="mfn-preamble"><p><strong>Prostatype Genomics (”Prostatype Genomics” or ”the Company”) announces that Aktiespararna has published a research report in which the target price for the Company is set at 0.12 SEK per share, and thus sees "a large upside compared to today's levels".</strong></p></div><div class="mfn-body"><p>In the research report, the global addressable market for the gene test Prostatype® is estimated at 5.8 billion SEK annually, of which the United States is estimated to make up approximately 65 percent (3.8 billion SEK). Prostatype Genomics expects Prostatype® to be approved for reimbursement by Medicare in the United States in Q4 2024, which would represent a key milestone for the Company, and the research report assumes that the main sales revenue is expected to come from this market.</p><p>A summary of the research report can be read on Aktiespararna's website:<br><a rel="noopener" href="https://www.aktiespararna.se/analyser/prostatype-genomics-blickarna-riktade-mot-pagaende-usa-lansering">https://www.aktiespararna.se/analyser/prostatype-genomics-blickarna-riktade-mot-pagaende-usa-lansering</a></p><p>The complete research report can be read directly via this link:<br><a rel="noopener" href="https://storage.mfn.se/b311ab7d-a498-4824-9986-9a365e9226f9/reinitieringsanalys-prostatype-genomics-maj-2024.pdf">https://storage.mfn.se/b311ab7d-a498-4824-9986-9a365e9226f9/reinitieringsanalys-prostatype-genomics-maj-2024.pdf</a></p></div><div class="mfn-footer mfn-contacts mfn-7901a8e48701"><p><strong class="mfn-heading-1">Contacts</strong><br><strong>For further information about Prostatype Genomics, please contact:</strong><br>Fredrik Rickman (previously Persson), CEO Prostatype Genomics AB<br>Telephone: +46 (0) 73 049 77 01.<br>e-mail: fredrik.persson@prostatypegenomics.com</p><p><strong>Certified Advisor</strong><br>Carnegie Investment Bank AB (publ), +46 (0)73 856 42 65, certifiedadviser@carnegie.se</p></div><div class="mfn-footer mfn-about mfn-a79541938641"><p><strong class="mfn-heading-1">About Us</strong><br><strong>About Prostatype Genomics AB</strong><br>Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/133d01b7-8a62-4181-9e94-47e77f89d1ba/prostatype-genomics-aktiespararna-sees-large-upside-for-the-share-in-research-report-with-target-price-0-12-sek-per-share.pdf" class="mfn-generated mfn-primary">Prostatype Genomics: Aktiespararna sees large upside for the share in research report with target price 0.12 SEK per share</a></p></div>

Prostatype Genomics: Aktiespararna sees large upside for the share in research report with target price 0.12 SEK per share